# Amply Discovery

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amply-discovery

- Industry: Biotechnology
- Headquarters: Belfast, UK
- Website: www.amplydiscovery.com
- Total disclosed funding: $2.4M
- Latest round: Seed (Jan 27, 2026)
- Investors on record: 4

## About

Founded in 2021 and based in Belfast, UK, Amply Discovery Ltd. is a drug and nutraceutical discovery company that uses machine learning and artificial intelligence to develop next-generation pharmaceuticals along with replacing conventional antibiotics and help tackle AMR (antimicrobial resistance). In May 2025, Amply Discovery Ltd. raised USD 1.75 million in seed funding led by new investor Twin Path Ventures, with participation from other new investors Venture Science and British Business Bank. Returning investor Qubis and individual investors also participated in the round. The company provides Amplyfolio AI, an AI-based software platform built on IBM and Microsoft technologies used for finding alternative anti-infective drugs. As of September 2022, Amply Discovery is discussing its pipeline with prospective partners to deliver its discoveries to market across animal health problems with a focus on topical skin and tissue infection management. Amply Discovery plans to use its proceeds from May 2025 to create a new drug platform.

## Funding rounds

- Seed, Jan 27, 2026, $2.4M — British Business Bank, Qubis, Venture Science, Twin Path Ventures

## Investors

- British Business Bank (https://capitalatlas.ai/funds/british-business-bank) — Seed
- Qubis (https://capitalatlas.ai/funds/qubis) — Seed
- Venture Science (https://capitalatlas.ai/funds/venture-science) — Seed
- Twin Path Ventures (https://capitalatlas.ai/funds/twin-path-ventures) — Seed